Disease Info Card

Benign Prostatic Hypertrophy

Information about Benign Prostatic Hypertrophy: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Benign Prostatic Hypertrophy

Most recent studies have shown that Benign Prostatic Hypertrophy shares some biological mechanisms with adenocarcinoma, bladder-neck-obstruction, carcinoma, erectile-dysfunction, hemorrhage, hyperplasia, hypertrophy, lower-urinary-tract-symptoms, malignant-neoplasm-of-prostate, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasm-metastasis, neoplasms, prostatic-diseases, prostatic-hyperplasia, prostatic-hypertrophy, prostatic-neoplasms, prostatitis, urethral-diseases, urination-disorders.

Among the many pathways, these few ones have gauged particular interests from scientists studying Benign Prostatic Hypertrophy, and have been seen in publications frequently: Aging, Angiogenesis, Cell Adhesion, Cell Cycle, Cell Death, Cell Growth, Cell Proliferation, Coagulation, Enucleation, Excretion, Hemostasis, Localization, Methylation, Micturition, Muscle Contraction, Pathogenesis, Reflex, Reverse Transcription, Secretion, Translation

Quite a number of genes have been found to play important roles in Benign Prostatic Hypertrophy, such as AKR1B1, AR, AREG, ASAP1, ASAP2, EGF, FDXR, KLK3, MRPS30, NPEPPS, PAPOLA, PDAP1, PLAG1, PROS1, PSAT1, PVR, REG3A, TUSC2, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.